Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 3, 1997, Pages 511-514

  Kihira, K ^a   Satoh, K ^a   Saifuku, K ^a   Taniguchi, Y ^a   Takimoto, T ^a   Yamamoto, H ^a   Ido, K ^a   Yoshida, Y ^a   Kimura, K ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH BIOPSY; TASTE DISORDER;

EID: 0030851612     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00186.x     Document Type: Article

References (27)

1. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-7.
2. Moayyedi P, Sahay P, Tompkins DS, et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7: 835-40.
3. Labenz J, Stolte M, Ruhl GH, et al. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995; 7: 9-11.
4. Jaup BH, Norrby A. Low-dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995; 90: 943-5.
5. Bazzoli F, Zagari RM, Fossi S, et al. Efficacy and tolerability of a short-term, low-dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 1993; 104: A40(Abstract).
6. Satoh K, Kimura K, Yoshida Y, et al. A topographical relationship between Helicobacter pylori and gastritis: Quantitative assessment of Helicobacter pylori in the gastric mucosa. Am J Gastroenterol 1991; 86: 285-91.
7. Satoh K, Kimura K, Kihira K, et al. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am J Gastroenterol 1996; 91: 963-9.
8. Kimura K, Satoh K, Kihira K, et al. A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 60-3.
9. Labenz J, Borsch G. Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. Am J Gastroenterol 1995; 90: 692-4.
10. 2-Receptor antagonists and Helicobacter pylori eradication. Scand J Gastroenterol 1995; 30 (Suppl. 212): 126-7.
11. Adamek RJ, Labenz J, Opferkuch W, et al. Ranitidine/amoxicillin vs. omeprazole/amoxicillin for cure of H. pylori positive gastric ulcer-role of acid suppression. Gastroenterology 1995; 108: A44 (Abstract).
12. Frotz H. M.D., Ahrens H, Hebbeln H, et al. Ranitidine plus Clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease. Gastroenterology 1995; 108: A96(Abstract).
13. Malanoski GJ, Eliopoulos GM, Ferraro MJ, et al. Effect of pH on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microb Infect Dis 1993; 12: 131-3.
14. Hardy DJ, Hanson CW, Hensey DM, et al. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-6.
15. Megraud F. Rational for the choice of antibiotics for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7(Suppl.): S49-54.
16. Moayyedi P, Sahay P, Tompkins DS, et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7: 835-40.
17. Kihira K, Yoshida Y, Kimura K, et al. Effect of a proton pump inhibitor AG-1749 (lansoprazole) on intragastric pH. Jpn J Gastroenterol 1991; 88: 672-80.
18. 2-antagonists. Gastroenterology 1985; 88: 1842-51.
19. Howden CW, Tsai HH, Reid JL, et al. Twenty-four hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times daily. Aliment Pharmacol Ther 1989; 3: 253-8.
20. Gotz JM, Veenendaal RA, Veselic M, et al. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. Scand J Gastroenterol 1995; 30(Suppl. 212): 34-7.
21. Adamek RJ, Opferkuch W, Wegener M, et al. Modified short-term triple therapy - Ranitidine, clarithromycin and metronidazole - for cure of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 168-9 (Letter).
22. Yousfi MM, Zimaity HMT, Graham DY, et al. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther 1996; 10: 119-22.
23. Yamagata K, Ishimori A, Satho K, et al. Report by Gastric Analysis Examination Committee. Jpn J Gastroenterol 1983; 80: 289-93 (in Japanese).
24. Isselbacher KJ, Braounwald E, Wilson JD, et al. (eds) Harrison's Principle of Internal Medicine, 13th edn: McGraw-Hill Inc., 1994: 2491-2.
25. Brooks FP. Tests related to the stomach. Bockus' Gastroenterol 1985; 1: 367-77.
26. Kihira K, Satoh K, Kimura K, et al. A 2-hour topical therapy for the treatment of Helicobacter pylori infection. Gut 1995; 37(Suppl.): A44(Abstract).
27. Kihira K, Satoh K, Taniguchi Y, Kimura K. An endoscopic topical therapy for the treatment of Helicobacter pylori infection. J Gastroenterol 1996, 31 (Suppl. IX): 66-8.